Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Capecitabine Maintenance in Metastatic Colorectal Cancer
NCT00623805Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2008
- Primary completion
- May 2012
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, capecitabine in colorectal adenocarcinoma, sponsored by Roche. Started Mar 2008; status: completed.
02
Drugs
bevacizumabcapecitabine
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT00623805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623805.